Q1 2013 Investor Conference Call Presentation Charts

1. Q1 2013 Results
Investor Conference Call
April 25, 2013 / Marijn Dekkers, CEO

2. Disclaimer
This presentation may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management.
Various known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation,
development or performance of the company and the estimates given here.
These factors include those discussed in Bayer’s public reports which are
available on the Bayer website at www.bayer.com.
The company assumes no liability whatsoever to update these forward-looking
statements or to conform them to future events or developments.
• Q1 2013 Investor Conference Call • Marijn DekkersPage 2

3. Page 3
Q1 2013 – LifeScience Businesses Off To A
Good Start
 HealthCare benefits from successful launch of new products and strong
growth in Consumer Care
 CropScience continues to grow profitably in ongoing favorable market
environment
 Cost pressure at MaterialScience resulted in earnings performance
below expectations
 Group sales organically +4%; reported EBIT +9%; adjusted* EBITDA
at prior-year level
 Full-year 2013 Group outlook confirmed
• Q1 2013 Investor Conference Call • Marijn Dekkers
*before special items

4. Page 4
EBIT
in € million
+9%
1,771
1,631
Sales
in € million
% currency & portfolio adj.
+4%
10,266
10,054
EBITDA
adjusted**
in € million
0%
2,4532,443
Core EPS
in €
+2%
1.701.67
*Prior-year figures restated.
**before special items
Q1’13Q1’12* Q1’13Q1’12* Q1’13Q1’12* Q1’13Q1’12*
Q1 2013 – Total Group:
LifeSciences Commence Positively
• Q1 2013 Investor Conference Call • Marijn Dekkers

5. Regional Performance - Growth Led By USA
And Emerging Economies
Page 5
Africa &
Middle East
Eastern
Europe
Emerging Economies
Emerging
Economies¹
+7%
Others²
+8%
USA
+8%
Western Europe
-3%
Q1 2013 Group Sales by Region
Group €10,266m; +4%
~1,000
+8%
~1,400
+8%
~400
-7%~700
+13%
¹ Emerging economies include: Latin America, Asia w/o Japan, Australia,
New Zealand, Africa and Middle East incl. Turkey, Eastern Europe
² Others = Japan, Australia, New Zealand, Canada
³ Emerging Asia = Asia w/o Japan, Australia, New Zealand
In € million, ∆% yoy Fx adjusted
34%
12%32%
22%
Latin
America
Emerging
Asia³
• Q1 2013 Investor Conference Call • Marijn Dekkers

6. Q1 2013 –
Cash Flow And Net Debt Development
Page 6
+€491m 7.5
GCF oFCF
1,807
Invest-
ments
365 (38)
∆
y-o-y +13% -100%
NCF
327
+38% +43%
Dec 31, 2012 Mar 31, 2013
7.0
Q1 2013 Cash Flow Net Debt Development
Cash Flow in € million, Net Debt in € billion
• Q1 2013 Investor Conference Call • Marijn Dekkers

7. Q1 2013 – HealthCare: New Products and
Consumer Care Drive Growth
Page 7
*before special items
Q1 2013 Sales Earnings1
Pharma
+2% (+5%)
Consumer
Health
+3% (+5%)
36%
HealthCare €4,443m; +2% (+5%)
2,5641,879
Price
+1%
Volume
+4%
Fx
-3%
Portfolio
0%
In € million, ∆% yoy, () = Fx & portf. adjusted
Q1‘12 Q1‘13 Q1‘12 Q1‘13
740
832
441 445
+12%
+1%
1,181
1,277 +8%
341 +1%
861
953 +11%
520
343
Adj.
EBITDA*
Adj.
EBIT*
610 +17%
• Q1 2013 Investor Conference Call • Marijn Dekkers 1 Prior-year figures restated.

8. Q1 2013 – CropScience: ContinuouslyStrong
In Favorable Market Environment
Page 8
Crop Protection
+9% (+11%)
Environmental
Science
-12% (-10%)
Seeds
+1% (0%)
Q1 2013 Sales Earnings1
In € million, ∆% yoy, () = Fx & portf. adjusted
CropScience €2,764m; +6% (+7%)
Price
+3%
Volume
+4%
Fx
-2%
Portfolio
0%
2,111
Q1‘12 Q1‘13 Q1‘12 Q1‘13
984
1,081 +10%
864
969 +12%
Adj.
EBITDA*
Adj.
EBIT*
164
489
• Q1 2013 Investor Conference Call • Marijn Dekkers
*before special items
1 Prior-year figures restated.

9. Q1 2013 – MaterialScience: Cost Pressure
Prevented A Better Performance
Page 9
**CAS: Coatings, Adhesives, Specialties *** IO: Industrial Operations
Polyurethanes
+3% (+4%)
Polycarbonates
-6% (-6%)
CAS**
-3% (-3%)
Q1 2013 Sales Earnings1
In € million, ∆% yoy, () = Fx & portf. adjusted
*before special items
MaterialScience €2,775m; +0% (+0%)
Price
+4%
Volume
-4%
Fx
-1%
Portfolio
0%
1,469
663
IO***
+0% (+1%)
Q1‘12 Q1‘13 Q1‘12 Q1‘13
Adj.
EBITDA*
Adj.
EBIT*
279
204 -27%
121
43 -65%
467
176
• Q1 2013 Investor Conference Call • Marijn Dekkers 1 Prior-year figures restated.

10. FY 2013 Group Outlook Confirmed
Page 10
20121 ∆ vs. 2011 2013E
Sales €39.7bn +5%
+4-5% to
~€41bn*
adj. EBITDA €8.3bn +9%
mid-single-digit %
increase
Core EPS €5.30 +10%
high-single-digit %
increase
Sales ∆ Fx and portfolio adjusted, EBITDA before special items
*Assuming Fx rate of $1.29 per €
Outlook depends on specific planning assumptions as detailed in the Annual Report• Q1 2013 Investor Conference Call • Marijn Dekkers
1 2012 figures restated.

11. Q1 2013 Results
Investor Conference Call
April 25, 2013 / Marijn Dekkers, CEO